Schuepbach E - Search Results

1

Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors.

Nunn C, Rueping M, Langenegger D, Schuepbach E, Kimmerlin T, Micuch P, Hurth K, Seebach D, Hoyer D. Nunn C, et al. Among authors: schuepbach e. Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):95-103. doi: 10.1007/s00210-002-0673-4. Epub 2003 Jan 24. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12595949

2

SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist.

Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, Langenegger D, Bouhelal R, Hurth K, Neumann P, Troxler T, Pfaeffli P. Hoyer D, et al. Among authors: schuepbach e. Neurosci Lett. 2004 May 6;361(1-3):132-5. doi: 10.1016/j.neulet.2004.02.017. Neurosci Lett. 2004. PMID: 15135911

3

Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.

Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D. Cervia D, et al. Among authors: schuepbach e. Br J Pharmacol. 2003 May;139(1):109-21. doi: 10.1038/sj.bjp.0705235. Br J Pharmacol. 2003. PMID: 12746229 Free PMC article.

4

Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery.

Fehlmann D, Langenegger D, Schuepbach E, Siehler S, Feuerbach D, Hoyer D. Fehlmann D, et al. Among authors: schuepbach e. J Physiol Paris. 2000 May-Aug;94(3-4):265-81. doi: 10.1016/s0928-4257(00)00208-4. J Physiol Paris. 2000. PMID: 11088004

5

Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists.

Cervia D, Zizzari P, Pavan B, Schuepbach E, Langenegger D, Hoyer D, Biondi C, Epelbaum J, Bagnoli P. Cervia D, et al. Among authors: schuepbach e. Neuropharmacology. 2003 Apr;44(5):672-85. doi: 10.1016/s0028-3908(03)00031-5. Neuropharmacology. 2003. PMID: 12668053 Free article.

6

Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors.

Cervia D, Langenegger D, Schuepbach E, Cammalleri M, Schoeffter P, Schmid HA, Bagnoli P, Hoyer D. Cervia D, et al. Among authors: schuepbach e. Neuropharmacology. 2005 May;48(6):881-93. doi: 10.1016/j.neuropharm.2004.12.019. Neuropharmacology. 2005. PMID: 15829258 Free article.

7

Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors.

Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Callander GE, et al. Among authors: schuepbach e. Front Neurosci. 2013 Dec 3;7:230. doi: 10.3389/fnins.2013.00230. eCollection 2013. Front Neurosci. 2013. PMID: 24376396 Free PMC article.

8

The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.

Mang GM, Dürst T, Bürki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE. Mang GM, et al. Among authors: schuepbach e. Sleep. 2012 Dec 1;35(12):1625-35. doi: 10.5665/sleep.2232. Sleep. 2012. PMID: 23204605 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page